newsfilter
← Latest News
GlobeNewswire·

First Subject Dosed in Small Pharma's First-in-Human Phase I Clinical Trial with SPL028

SPL028 is a proprietary deuterated DMT candidate with multi-layered IP protection Phase I study will compare two routes of SPL028 administration; intravenous and intramuscular LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE)